Cumberland Research Associates | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease	Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder	Active, not recruiting	Phase 2 / Phase 3	2026-09-28		NCT03466411
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )	Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease	Active, not recruiting	Phase 3	2026-07-02		NCT04849728
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis	Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease	Active, not recruiting	Phase 3	2026-06-01		NCT03900429
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)	Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndrome	Active, not recruiting	Phase 3	2026-05-27		NCT04951219